Switch theme
Sign up to access all valuation multiples
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
1977
452
LTM Revenue $203M
LTM EBITDA $22.3M
$578M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Axogen has a last 12-month revenue (LTM) of $203M and a last 12-month EBITDA of $22.3M.
In the most recent fiscal year, Axogen achieved revenue of $187M and an EBITDA of $6.1M.
Axogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Axogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $203M | XXX | $187M | XXX | XXX | XXX |
| Gross Profit | $151M | XXX | $142M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $22.3M | XXX | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 3% | XXX | XXX | XXX |
| EBIT | $1.9M | XXX | -$3.3M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -2% | XXX | XXX | XXX |
| Net Profit | -$3.9M | XXX | -$10.0M | XXX | XXX | XXX |
| Net Margin | -2% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $19.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Axogen's stock price is $12.
Axogen has current market cap of $531M, and EV of $578M.
See Axogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $578M | $531M | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Axogen has market cap of $531M and EV of $578M.
Axogen's trades at 3.1x EV/Revenue multiple, and 95.1x EV/EBITDA.
Equity research analysts estimate Axogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Axogen has a P/E ratio of -135.7x.
See valuation multiples for Axogen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $531M | XXX | $531M | XXX | XXX | XXX |
| EV (current) | $578M | XXX | $578M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 25.9x | XXX | 95.1x | XXX | XXX | XXX |
| EV/EBIT | 310.7x | XXX | -175.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -135.7x | XXX | -53.3x | XXX | XXX | XXX |
| EV/FCF | 511.3x | XXX | 52533.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAxogen's last 12 month revenue growth is 16%
Axogen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Axogen's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Axogen's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Axogen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 8% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Axogen acquired XXX companies to date.
Last acquisition by Axogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Axogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Axogen founded? | Axogen was founded in 1977. |
| Where is Axogen headquartered? | Axogen is headquartered in United States of America. |
| How many employees does Axogen have? | As of today, Axogen has 452 employees. |
| Who is the CEO of Axogen? | Axogen's CEO is Mr. Michael J. Dale. |
| Is Axogen publicy listed? | Yes, Axogen is a public company listed on NAS. |
| What is the stock symbol of Axogen? | Axogen trades under AXGN ticker. |
| When did Axogen go public? | Axogen went public in 1986. |
| Who are competitors of Axogen? | Similar companies to Axogen include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Axogen? | Axogen's current market cap is $531M |
| What is the current revenue of Axogen? | Axogen's last 12 months revenue is $203M. |
| What is the current revenue growth of Axogen? | Axogen revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Axogen? | Current revenue multiple of Axogen is 2.8x. |
| Is Axogen profitable? | Yes, Axogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Axogen? | Axogen's last 12 months EBITDA is $22.3M. |
| What is Axogen's EBITDA margin? | Axogen's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Axogen? | Current EBITDA multiple of Axogen is 25.9x. |
| What is the current FCF of Axogen? | Axogen's last 12 months FCF is $1.1M. |
| What is Axogen's FCF margin? | Axogen's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Axogen? | Current FCF multiple of Axogen is 511.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
